Use of medications or devices for erectile dysfunction among long-term prostate cancer treatment survivors: Potential influence of sexual motivation and/or indifference

被引:74
作者
Miller, David C.
Wei, John T.
Dunn, Rodney L.
Montie, James E.
Pimentel, Hector
Sandler, Howard M.
McLaughlin, P. William
Sanda, Martin G.
机构
[1] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Urol, Boston, MA 02215 USA
[2] Univ Michigan, Med Ctr, Dept Radiat Oncol, Ann Arbor, MI 48109 USA
[3] Univ Michigan, Med Ctr, Michigan Urol Ctr, Ann Arbor, MI 48109 USA
关键词
D O I
10.1016/j.urology.2006.01.077
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives. To evaluate the potential association between sexual motivation and patterns of erectile dysfunction (ED) therapy among a large cohort of localized prostate cancer treatment survivors. Methods. The use of medications and devices to improve erections and sexual health-related quality of life (HRQOL) were evaluated using a mailed Expanded Prostate Cancer Index Composite survey administered to 896 men 4 to 8 years after brachytherapy, three-dimensional conformal external beam radiotherapy (3D-CRT), or radical prostatectomy and 112 control men. The responding participants (73% of those surveyed) were classified by prostate cancer treatment, sexual motivation, and ED therapy use. Bivariate and multivariate analyses were used to identify the factors associated with ED therapy use and sexual HRQOL outcome. Results. The quality of erections unassisted by medications or devices was not different among the treatment groups. Prostate cancer survivors used medications or devices for ED more commonly than did the control men (30% versus 13%; P < 0.01). One half of the prostate cancer survivors with ED reported indifference regarding their ED (small to no sexual bother despite absent or poor unassisted erections). Conversely, among men who were bothered by poor erections, 48% of the brachytherapy, 61% of the 3D-CRT, and 23% of radical prostatectomy subjects had never tried commonly available medications or devices to improve their erections (P < 0.01). The current use of at least one erection aid was an independent determinant of more favorable sexual HRQOL (P < 0.01). Conclusions. Many men who are bothered by posttreatment ED reported never having tried medications or devices to improve their erections. The lack of ED therapy was more prevalent among patients with erectile concerns after brachytherapy or 3D-CRT than after radical prostatectomy, suggesting possible opportunities for improving sexual HRQOL among long-term survivors.
引用
收藏
页码:166 / 171
页数:6
相关论文
共 16 条
[1]   Comparison of recommendations by urologists and radiation oncologists for treatment of clinically localized prostate cancer [J].
Fowler, FJ ;
Collins, MM ;
Albertsen, PC ;
Zietman, A ;
Elliott, DB ;
Barry, MJ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (24) :3217-3222
[2]   Neoadjuvant hormonal therapy impairs sexual outcome among younger men who undergo external beam radiotherapy for localized prostate cancer [J].
Hollenbeck, BK ;
Wei, JT ;
Sanda, MG ;
Dunn, RL ;
Sandler, HM .
UROLOGY, 2004, 63 (05) :946-950
[3]   Neoadjuvant hormonal therapy and older age are associated with adverse sexual health-related quality-of-life outcome after prostate brachytherapy [J].
Hollenbeck, BK ;
Dunn, RL ;
Wei, JT ;
McLaughlin, PW ;
Han, M ;
Sanda, MG .
UROLOGY, 2002, 59 (04) :480-484
[4]   Efficacy of sildenafil in an open-label study as a continuation of a double-blind study in the treatment of erectile dysfunction after radiotherapy for prostate cancer [J].
Incrocci, L ;
Hop, WCJ ;
Slob, AK .
UROLOGY, 2003, 62 (01) :116-120
[5]   Treatment of erectile dysfunction with sildenafil citrate (Viagra) after radiation therapy for prostate cancer [J].
Kedia, S ;
Zippe, CD ;
Agarwal, A ;
Nelson, DR ;
Lakin, MM .
UROLOGY, 1999, 54 (02) :308-312
[6]  
MCNAUGHTON CM, 2002, UROLOGY, V60, P628
[7]   Long-term outcomes among localized prostate cancer survivors: Health-related quality-of-life changes after radical prostatectomy, external radiation, and brachytherapy [J].
Miller, DC ;
Sanda, MG ;
Dunn, RL ;
Montie, JE ;
Pimentel, H ;
Sandler, HM ;
McLaughlin, WP ;
Wei, JT .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (12) :2772-2780
[8]   Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: The prostate cancer outcomes study [J].
Potosky, AL ;
Davis, WW ;
Hoffman, RM ;
Stanford, JL ;
Stephenson, RA ;
Penson, DF ;
Harlan, LC .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (18) :1358-1367
[9]   Long-term effect of sildenafil citrate on erectile dysfunction after radical prostatectomy: 3-year follow-up [J].
Raina, R ;
Lakin, MM ;
Agarwal, A ;
Sharma, R ;
Goyal, KK ;
Montague, DK ;
Klein, E ;
Zippe, CD .
UROLOGY, 2003, 62 (01) :110-115
[10]   The use of treatments for erectile dysfunction among survivors of prostate carcinoma [J].
Schover, LR ;
Fouladi, RT ;
Warneke, CL ;
Neese, L ;
Klein, EA ;
Zippe, C ;
Kupelian, PA .
CANCER, 2002, 95 (11) :2397-2407